Welcome to our website

Help us direct you to the right information by selecting one of the following options:

I'm a Healthcare Professional

The content on this website is intended for U.S. Healthcare Professionals. By entering this website, you confirm you are a U.S. Healthcare Professional

I am a Healthcare Professional

I'm NOT a Healthcare Professional

The content on this website is intended for Healthcare Professionals only.

For more information about a prescription treatment option, click below

I am NOT a Healthcare Professional


You are now leaving this website and are going to a website that is not operated by EMD Serono. We are not responsible for the content or availability of linked sites.

If you have any questions or concerns about the products and services offered on linked third-party websites, please contact the third party directly.


Cladribine Tablets: latest safety analysis


Updated safety of Cladribine Tablets in the treatment of patients with multiple sclerosis: integrated safety analysis and post-approval data

Cook S, Giovannoni G, Leist T et al.

Presented at the Consortium of Multiple Sclerosis Centers (CMSC) Virtual Poster/Platform Session, August 3, 2020

Download PDF




• Update to the integrated analysis from the Cladribine Tablets clinical trial program (data cut-off October 2018)

• Contains information on the rate of serious treatment-emergent adverse events, infections, lymphopenia and malignancies

• Also contains post-approval safety data from the first patients to receive commercial Cladribine Tablets, cumulative to January 2020 – including information on cases of COVID-19